Myomo Inc (MYO)
:MYO
MYO Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MYO Stock 12 Month Forecast
Average Price Target
$4.32
▲(544.78% Upside)
| Highest Price Target$9.50 | Average Price Target$4.32 | Lowest Price Target$1.10 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Alliance Global Partners
$4→$3
Buy
347.76%
Upside
Reiterated
03/12/26
Ascendiant
$10→$9.5
Buy
1317.91%
Upside
Reiterated
03/11/26
We are maintaining our 2026 estimates for revenue of $43 million, but adjusting it for EPS to $(0.32) from $(0.27). We are initiating our 2027 estimates for revenue of $45 million, and for EPS of $(0.25). Focused on MyoPro commercialization: Myomo’s main product, the MyoPro custom fabricated myoelectric upper limb orthosis, is like an exoskeleton for the upper body. Myomo estimates that the addressable U.S. market for its products is $10 billion. Myomo launched the MyoPro 2x, the latest evolution in its flagship MyoPro product line. Key catalysts expected in 2026: Key catalysts expected in 2026 include continued momentum in U.S. commercialization (particularly improved reimbursement and ramping Medicare coverage), and commercialization in Europe and international (which is only ~20% of revenues).
Craig-Hallum
$2→$1.1
Buy
64.18%
Upside
Assigned
03/10/26
H.C. Wainwright
$5
Buy
646.27%
Upside
Reiterated
03/10/26
Maxim Group
$4→$3
Buy
347.76%
Upside
Reiterated
03/10/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Alliance Global Partners
$4→$3
Buy
347.76%
Upside
Reiterated
03/12/26
Ascendiant
$10→$9.5
Buy
1317.91%
Upside
Reiterated
03/11/26
We are maintaining our 2026 estimates for revenue of $43 million, but adjusting it for EPS to $(0.32) from $(0.27). We are initiating our 2027 estimates for revenue of $45 million, and for EPS of $(0.25). Focused on MyoPro commercialization: Myomo’s main product, the MyoPro custom fabricated myoelectric upper limb orthosis, is like an exoskeleton for the upper body. Myomo estimates that the addressable U.S. market for its products is $10 billion. Myomo launched the MyoPro 2x, the latest evolution in its flagship MyoPro product line. Key catalysts expected in 2026: Key catalysts expected in 2026 include continued momentum in U.S. commercialization (particularly improved reimbursement and ramping Medicare coverage), and commercialization in Europe and international (which is only ~20% of revenues).
Craig-Hallum
$2→$1.1
Buy
64.18%
Upside
Assigned
03/10/26
H.C. Wainwright
$5
Buy
646.27%
Upside
Reiterated
03/10/26
Maxim Group
$4→$3
Buy
347.76%
Upside
Reiterated
03/10/26
Best Analysts Covering Myomo
3 Months
xxx
Success Rate
8/14 ratings generated profit
Average Return
+18.27%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +18.27% per trade.
1 Year
Success Rate
5/13 ratings generated profit
Average Return
+95.13%
reiterated a buy rating 26 days ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +95.13% per trade.
2 Years
xxx
Success Rate
5/13 ratings generated profit
Average Return
+94.38%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of +94.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MYO Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
4
4
0
5
5
Buy
1
1
0
0
0
Hold
55
47
32
35
16
Sell
5
3
0
0
0
Strong Sell
0
0
0
0
0
total
65
55
32
40
21
Each month's total comprises the sum of three months' worth of ratings.
MYO Financial Forecast
MYO Stock Forecast FAQ
What is MYO’s average 12-month price target, according to analysts?
Based on analyst ratings, Myomo Inc’s 12-month average price target is 4.32.
What is MYO’s upside potential, based on the analysts’ average price target?
Myomo Inc has 544.78% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MYO a Buy, Sell or Hold?
Myomo Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Myomo Inc’s price target?
The average price target for Myomo Inc is 4.32. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.50 ,the lowest forecast is $1.10. The average price target represents 544.78% Increase from the current price of $0.67.
The highest analyst price target is $9.50 ,the lowest forecast is $1.10. The average price target represents 544.78% Increase from the current price of $0.67.
What do analysts say about Myomo Inc?
Myomo Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of MYO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.